SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~February~~April 1925, 2016

~~REVE~~ CANTECH ~~TECHNOLOGIES~~HOLDING, INC.

(Exact name of Company as specified in its charter)

Nevada	000-54497	27-2571663
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	300 S El Camino Real San Clemente, California 92672
	109 E. 17th Street, Suite 80 Cheyenne, Wyoming 82001
	(Address of principal executive offices)
	Phone: (714) 907-1241
	Phone: (626) 429-4948
	(Company’s Telephone Number) 17011 Beach Boulevard, Suite 900 Huntington Beach, California 92647
	(Company’s Telephone Number) Reve Technologies, Inc. 300 S El Camino Real San Clemente, California 92672

(Registrant’s Previous Name and Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

The number of issued and outstanding shares of Common Stock as at ~~February~~June 221, 2016, is 13,~~251~~475,~~189~~599,~~865~~703

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Effective April 19, 2016 the Registrant and certain preferred shareholders of the Registrant entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Canteck Pharma, Inc., a Delaware corporation (“Canteck” or“CKPH”) and certain majority shareholders of CKPH. Canteck has developed and has patented technology (US8,067,531B2) and also known as Irreversible Pepsin Fraction (“IPF”). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.

The Purchase Agreement sets forth the plan through which the Registrant purchases from Seller, on the terms and conditions set forth in the Purchase Agreement, Sellers One Hundred Percent (100%) ownership Interest in CanTeck Pharma for its current and planned operations for the country of Mexico (“CPMO”) and the exclusive Sub Licensing Agreement therewith for Irreversible Pepsin Fraction specific to the Cancer indication only, for the entire country of Mexico (the “License”); Registrant. As consideration for the Purchase, the shareholders of Canteck and or Canteck per its directive will receive controlling interest through acquiring herewith 667,000 of Registrants Series B preferred shares, to be amended to be non-dilutable, along with an amount of shares related of the purchase of the Exclusive Sub License equal to 60% of the then-issued and outstanding common stock of the Company, also to be non-dilutable. On the Closing Date Registrant shall also assume for its exclusive Sub Licensing Agreement aportion of the total liabilities due under the Exclusive Master Licensing Agreement by Canteck to the Zhabilov Trust in the allocated amount comprised of a $500,000 fee and $100,000 of other liabilities, the resulting total amountof Six Hundred Thousand ($600,000.00) US Dollars...The exclusive sub Licensing Agreement is for Irreversible Pepsin Fraction specific to the Cancer indication only, for the entire country of Mexico, or officially known as the United Mexican States.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

See Item 1.01 above.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

Securities Issued (Preferred Shares)

On April 19, 2016, the Company issued 667,000 shares of Series B Voting Preferred Stock to Canteck Pharma, Inc. representing 66.7% of the total issued and outstanding shares of the Company’s Series B Voting Preferred Stock.

Each share of Series B Voting Preferred Stock is equal to and counted as 1,000 times the vote of all of the shares of the Corporation (i) common stock, and (ii) other voting preferred stock issued and outstanding on the date of each and every vote or consent of the shareholders of the Company regarding each and every matter submitted to the shareholders of the Company for approval.

Consideration

The consideration for the 1,000,000 shares of Series B Voting Preferred Stock was in behalf of certain of the terms of the Purchase Agreement with Canteck Pharma, Inc. described herein. See also Exhibit 10.1 to this Current Report.

Exemption from Registration

The 1,000,000 shares of the Series B Voting Preferred Stock were issued in reliance upon that exemption from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), specified by the provisions of Section 4(2) of the Act regarding transactions by an issuer not involving a public offering of securities. The issuance of those shares as conversion of the Indebtedness did not involve any public offering of securities.

Securities Issued (Common Shares)

OnAdditional ~~January~~Issuances ~~14,~~from ~~2016, Blackbridge Capital, LLC converted a portion of a~~ Convertible Promissory ~~Note wherein 69,500,000 shares of the Company’s Common Stock were issued, representing 7.557% of the issued and outstanding shares of Common Stock.~~Notes

OnDuring ~~January~~the 14period commencing April 24, 2016 through June 1, ~~RDW~~2016, ~~Capital~~the Company issued 2,285,409,838 ~~LLC~~common ~~converted~~shares ato ~~portion~~reduce ofdebt aon ~~Convertible~~certain ~~Promissory~~convertible ~~Note~~promissory ~~wherein~~notes. ~~32,500,000~~The issued and outstanding common shares of the Company’s, ~~Common~~at ~~Stock~~the ~~were~~beginning ~~issued~~of the period commencing April 24, ~~representing~~2016, was 1,251,189,865 shares and 3~~.534%~~,475,599,703 at the end of the ~~issued~~period, ~~and~~with ~~outstanding~~further ~~shares~~detail ofmore ~~Common~~fully ~~Stock.~~described as follows:

On January 14, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 46,221,000 shares of the Company’s Common Stock were issued, representing 5.026% of the issued and outstanding shares of Common Stock.

On January 19, 2016, JMJ Financial converted a portion of a Convertible Promissory Note wherein 38,400,000 shares of the Company’s Common Stock were issued, representing 4.008% of the issued and outstanding shares of Common Stock.

On January 20, 2016, Typenex Co Investment, LLC converted a portion of a Convertible Promissory Note wherein 70,100,000 shares of the Company’s Common Stock were issued, representing 6.818% of the issued and outstanding shares of Common Stock.

On January 26, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 81,238,094 shares of the Company’s Common Stock were issued, representing 6.492% of the issued and outstanding shares of Common Stock.

On January 26, 2016, RDW Capital, LLC converted a portion of a Convertible Promissory Note wherein 40,000,000 shares of the Company’s Common Stock were issued, bringing the total of its beneficial ownership to 3.196% of the issued and outstanding shares of Common Stock.

On January 26, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 101,828,800 shares of the Company’s Common Stock were issued, representing 8.138% of the issued and outstanding shares of Common Stock.

Consideration

The consideration for the shares of Common Stock issued were presentation of a Notice of Conversion relative to a Convertible Promissory Note(s).

OnConvertible ~~April~~Promissory ~~19,~~Note 2016, One Hundred Seventy Two Million Thirty Nine Thousand Three Hundred and Three (172,039,303) shares of the Company’s Common Restricted Stock were agreed to be issued to Mr. Dennis Alexander, representing 4.95% of the issued and outstanding shares of Common Stock, in exchange for the return of 333,500 shares of his Series B Voting Preferred Stock toward the Registrants Purchase Agreement with Cantech Pharma, Inc. and retains 166,500 of Series B Voting Preferred Stock. The shares shall have non dilutable provisions.Conversions:

On April 1925, 2016, ~~One~~Blackbridge ~~Hundred~~Capital, ~~Seventy~~LLC ~~Two~~converted ~~Million~~a ~~Thirty~~portion ~~Nine~~of ~~Thousand~~a ~~Three~~Convertible ~~Hundred~~Promissory ~~and~~Note ~~Three~~wherein ~~(172~~120,~~039~~000,~~303)~~000 shares of the Company’s Common ~~Restricted~~ Stock were ~~agreed to be~~ issued ~~to Mrs. Joanne M. Sylvanus~~, representing 48.9575% of the issued and outstanding shares of Common Stock, into ~~exchange~~reduce ~~for~~debt ~~her~~on ~~return~~convertible ofpromissory ~~333,500~~notes ~~shares~~in ~~of her Series B Voting Preferred Stock toward~~ the ~~Registrants~~amount ~~Purchase~~of ~~Agreement with Cantech Pharma, Inc~~$600. ~~The shares shall have non dilutable provisions.~~

On April 1928, 2016, ~~Two~~Blackbridge ~~Billion~~Capital, ~~Two~~LLC ~~Hundred~~converted ~~Twenty~~a ~~Million~~portion ~~Eight~~of ~~Hundred~~a ~~Sixty~~Convertible ~~Three~~Promissory ~~Thousand~~Note ~~Four~~wherein ~~Hundred and Four (2~~130,~~220~~000,~~863,404)~~ 000 shares of the Company’s Common ~~Restricted~~ Stock were ~~agreed to be~~ issued ~~to Canteck Pharma~~, ~~Inc.,~~ representing 548.0565% of the issued and outstanding shares of Common Stock, into ~~behalf~~reduce ofdebt ~~the~~on ~~Purchase~~convertible ~~Agreement~~promissory ~~with~~notes ~~Cantech.~~in ~~The~~the ~~shares~~amount ~~shall~~of ~~have non dilutable provisions~~$650.

On April 1929, 2016, ~~Six~~Blackbridge ~~Hundred~~Capital, ~~and~~LLC ~~Sixty~~converted ~~Seven~~a ~~Thousand,~~portion ~~(667,000) shares~~ of ~~the~~a ~~Registrants~~Convertible ~~Series~~Promissory BNote ~~Voting~~wherein ~~Preferred~~130,000,000 ~~Stock~~shares ~~toward~~of the ~~Registrants~~Company’s ~~Purchase~~Common ~~Agreement~~Stock were ~~agreed to be~~ issued ~~to Canteck Pharma~~, ~~Inc..,~~ representing ~~66.~~7.96% of the issued and outstanding shares of ~~Series~~Common ~~B Voting Preferred~~ Stock, into ~~behalf~~reduce ofdebt ~~the~~on ~~Purchase~~convertible ~~Agreement~~promissory ~~with~~notes ~~Cantech.~~in ~~The~~the ~~shares~~amount ~~shall~~of ~~have non dilutable provisions~~$650.

On May 2, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 148,635,000 shares of the Company’s Common Stock were issued, representing 5.026% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $7,431.77.

On May 3, 2016, Typenex Co Investment, LLC converted a portion of a Convertible Promissory Note wherein 70,100,000 shares of the Company’s Common Stock were issued, representing 9.06% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $7,987.50.

On May 4, 2016, LG Capital Funding, LLC converted a portion of a Convertible Promissory Note wherein 88,586,129 shares of the Company’s Common Stock were issued, representing 4.32% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $5,492.34.

On May 4, 2016, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 180,000,000 shares of the Company’s Common Stock were issued, representing 8.08% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $900.

On May 5, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 148,484,600 shares of the Company’s Common Stock were issued, representing 6.25% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $7,424.23

On May 6, 2016, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 215,800,000 shares of the Company’s Common Stock were issued, representing 8.33% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $1,079.

On May 12, 2016, LG Capital Funding, LLC converted a portion of a Convertible Promissory Note wherein 88,815,645 shares of the Company’s Common Stock were issued, representing 3.31% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $5,506.57.

On May 12, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 49,340.000 shares of the Company’s Common Stock were issued, representing 1.80% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $246.70.

On May 12, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 95,240,000 shares of the Company’s Common Stock were issued, representing 3.37% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $4,762.

On May 12, 2016, LG Capital Funding, LLC converted a portion of a Convertible Promissory Note wherein 88,938,064 shares of the Company’s Common Stock were issued, representing 3.05% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $5,514.16.

On May 18, 2016, Typenex Co Investment, LLC converted a portion of a Convertible Promissory Note wherein 282,000,000 shares of the Company’s Common Stock were issued, representing 8.82% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $12,690.

On May 25, 2016, Typenex Co Investment, LLC converted a portion of a Convertible Promissory Note wherein 282,070,000 shares of the Company’s Common Stock were issued, representing 8.11% of the issued and outstanding shares of Common Stock to reduce debt on convertible promissory notes in the amount of $12,693.15.

Exemption from Registration

The shares of Common Stock issued pursuant to Convertible Promissory Notes were issued in reliance upon that exemption from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), specified by the provisions of Section 4(2) of the Act regarding transactions by an issuer not involving a public offering of securities. The issuance of those shares as conversion of the Indebtedness did not involve any public offering of securities.

Additional Issuances from Convertible Promissory Notes

Additionally, during the period commencing January 14, 2016 through January 26, 2016 and unchanged through April 22, 2016, the Company issued 479,787,894 common shares to reduce debt on certain convertible promissory notes. The issued and outstanding common shares of the Company, at the beginning of the period commencing January 14, 2016, was 771,401, 971 shares.

Exemption from Registration

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) for the private placement of these securities pursuant to Section 4(2) of the Act and/or Rule 506 of Regulation D promulgated thereunder since, among other things, the transaction does not involve a public offering, the Investor is an “accredited investor” and/or qualified institutional buyer, the Investor has access to information about the Company and its investment, the Investor will take the securities for investment and not resale, and the Company is taking appropriate measures to restrict the transfer of the securities.

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT

The information set forth and incorporated by reference in Item 3.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

Identity of the person who acquired control; date and description of the transaction; and basis of control

On April 19, 2016, in behalf of the Registrants Purchase Agreement with Canteck Pharma, Inc. Mrs. Diana Zhabilov was appointed as Chairman, Mr. Harry Zhabilov was appointed as Chief Science Officer and Treasurer of the Company. Mr. Dennis Alexander continues appointment as Chief Executive Offer and Director, and Ms. Joanne M. Sylvanus continues appointment as Chief Financial Officer, Secretary and Director. It was further agreed that Valentine Dimitrov is to be appointed to the Board of Directors after the closing of the Purchase Agreement as a fifth Director.

In consideration for the terms of the Purchase Agreement between the Registrant and Cantech Pharma, Inc. which Cantech is owned by Mrs. Diana Zhabilov and who will be Chairman of the Registrant, Cantech will receive Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) of the Registrants common restricted stock and 667,000 shares of its Preferred Series B Voting Stock. Mr. Alexander will receive 172,039,303 shares of the Company’s Common Restricted Stock and retain 166,500 shares of Voting Preferred Stock and Ms. Sylvanus will receive 172,039,303 shares of the Company’s Common Restricted Stock and retain 166,500 shares of Voting Preferred Stock in behalf of the terms of the Registrants Purchase Agreement with Canteck. These issuances will render Canteck Pharma, Inc., Mrs. Diana Zhabilov who directly owns100% of Canteck, in control of the Company.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF OFFICERS; APPOINTMENT OF CERTAIN OFFICERS, COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

The information set forth and incorporated by reference in Item 3.02 and 5.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

On ~~April 19, 2016, in~~ behalf of the Registrants Purchase Agreement with Canteck Pharma, Inc. ~~Mrs.~~(noting ~~Diana~~this ~~Zhabilov~~is ~~was~~a ~~appointed~~different ascompany ~~Chairman~~ and ~~President of~~separate from the Registrant, and our new name change from Reve Technologies, Inc. to Cantech Holding, Inc.) on April 19, 2016 it was agreed that Mr. ~~Harry~~Valentine ~~Zhabilov~~Dimitrov was to be appointed to the Board of Directors after the closing of the Purchase Agreement as ~~Chief~~a ~~Science~~fifth ~~Officer~~Director and ~~Treasurer~~which is now effective concurrent and effective with the Registrants now effective change of corporate domicile and other actions further confirmed by the ~~Registrant~~filing its Foreign Profit Corporation Articles of Continuance effective May 27, 2016. (See Item 5.03 in this current report for further information)

ItA ~~was~~description ~~further~~of ~~agreed that Valentine Dimitrov is to be appointed to~~ the ~~Board~~business ofexperience ~~Directors~~during ~~after~~ the ~~closing~~past ofseveral ~~the~~years ~~Purchase~~for ~~Agreement~~our asnewest ~~a fifth~~ Director. ~~In consideration for the terms of the Purchase Agreement between the Registrant and Cantech Pharma, Inc~~Mr. ~~which~~Valentin ~~Cantech~~Lordanov Dimitrov is ~~owned~~set byforth Mrs. Diana Zhabilov, now acting Chairman of the Registrant, Cantech will receive 2,220,863,404 shares of the Registrants Common Restricted Stock and 667,000 shares of its Preferred Series B Voting Stock.below:

AMr. ~~description~~Valentin Lordanov Dimitrov serves as a Director of the ~~business~~Registrant ~~experience~~as ~~during~~of ~~the~~May ~~past~~27, ~~several~~2016. ~~years~~Mr. Dimitrovs qualifications include a Master’s degree in 2001 for ~~our~~Social ~~directors~~Pedagogics ~~and~~from ~~executive~~Kliment ~~officer~~Ohridski isUniversity, ~~set~~Bachelor ~~forth~~of International ~~below~~Diplomatic Relations in 2004 from Kiev State University, Ukraine. His pecializations include:

~~Mrs.~~1995 ~~Diana~~University ~~Zhabilov, serves as Chairman~~ of ~~the~~National ~~Registrant since April 19, 2016. Mrs. Zhabilov has served as an Educator~~ and ~~Clinical~~World ~~Instructor~~Economy ~~with~~– ~~Success~~Sofia ~~Education~~– ~~Colleges~~Finances; ~~from~~1999, ~~December~~Chemical-technological ~~2014~~University to- Sofia - ~~the~~Organic ~~present~~chemistry. ~~She~~Mr. ~~has~~Dimitrov ~~worked~~is atfluent ~~Dream~~in ~~Home~~English, ~~Health~~Russian, ~~from~~and ~~May~~spoken ~~2013~~in toGerman. Over the ~~present~~past ~~evaluating~~few ~~patients~~years ~~for~~since ~~immediate~~2007 ~~medical needs and plan of care~~Mr. ~~Education~~ ~~includes~~Dimitrov ~~Board~~has ofworked ~~Nursing~~as –a ~~Sacramento,~~Director ~~CA , Board~~ of ~~CNA~~ “Vital-Fe” ~~Sacramento,~~LTD ~~Reagan~~which ~~Career~~is ~~Institute~~involved ~~for~~in ~~Phlebotomy~~the ~~Tech~~distribution I,of ~~Golden Gate University~~bio-technology ~~San Francisco, CA, College of Nursing, Medical Academy, Sofia, Bulgaria. Certifications include VN 204027, Phlebotomy~~ and IVpharmaceutical ~~certified CA, CPR-BLS/AED, BSN in Nursing Diploma # 9357/1988 Sofia, Bulgaria~~products.

Mr. Harry H. Zhabilov, Jr., BSc, McS Science serves as Chief Science Officer and Treasurer of the Registrant, and is a Vice Chairman, President and Chief Science Officer of Immunotech Laboratories, Inc. Mr. Zhabilov Founded Immunotech Laboratories, Inc. He served as Vice Chairman, Chief Science Officer and Secretary of International Technology Systems, Inc. since December 2008. Mr. Zhabilov holds a degree of B.S and M.S. in chemistry and Chemical Engineering. He is a member of ACS, ALCHE.

Dennis R. Alexander has served CEO and Director of the Registrant since April 19, 2016 having served as Chairman, CEO and Director since November 2015. He served as a Director and CEO of Boomerang Oil, Inc listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange since March 2014 and as Chairman, Director, CEO, and President of the Mondial Ventures, Inc. since July 31, 2012. He has served as Chairman, CEO, and CFO of EGPI Firecreek, Inc. (“EGPI”) and President and Director of its wholly owned subsidiary Energy Producers, Inc. (“EPI”), engaged in oil and natural gas exploration, production, and development. Since May 21, 2009. Mr. Alexander served as Chairman, President and Chief Financial Officer of EGPI and Firecreek Petroleum, Inc., (“FPI”) which pursued oil and gas acquisitions internationally in certain Eurasian countries during the then trend up for oil. Since February 10, 2007 he has served as Chairman and Chief Financial Officer of EGPI and FPI since July 1, 2004 through February 9, 2007, having served as the President and Director of EGPI from May 18, 1999 to June 30, 2004. In September 1998 he was a founder, and from January 19, 1999 through its acquisition with EGPI served in various capacities as President and Director of Energy Producers Group, Inc., and was the original founding entity for EGPI and EPI. From April 1997 through March 1998 he served as CEO, Director, Consultant of Miner Communications, Inc., a media communications company. From April 26, 1997 through March, 1998 he was a director of Rockline, Inc., a private mining, resource company, and a founder of World Wide Bio Med, Inc., a private health-bio care, startup company. Since March 1996 to the present he has owned Global Media Network USA, Inc., which has included management consulting, advisory services. Mr. Alexander attended ASU studying Architecture from 1971 to 1974.

Joanne M. Sylvanus has served as a Director, Chief Financial Officer, and Secretary of the Registrant since November 2015. She served as a Director Chief Financial Officer of Boomerang Oil, Inc., listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange since March 2014 and as a Director, Chief Financial Officer of Mondial Ventures, Inc since July 31, 2012 and additionally as Secretary and Treasurer since November 7, 2012. She has been engaged by EGPI Firecreek, Inc. (“EGPI”) and its wholly owned subsidiary Energy Producers, Inc. (“EPI”) which is in the business of oil and natural gas exploration, production, and development as an accounting and tax consultant since December 1999 and May 21, 1999 respectively. She is the owner and sole proprietor of J.M. Sylvanus Accounting, since May 1974, which prepares Corporate, Partnership, Trust, and Estate Tax Returns, acts as Conservator and Trustee for Estates and Trusts, and provides consulting on Financial and Tax matters. She held a Certified Public Accounting certificate from the State of Arizona from October 1972 until May 1996 when she formally retired her certificate. Over the years from 1974 until May 1996, she was the owner and sole proprietor of J.M. Sylvanus CPA which conducted certified audits for not-for-profit organizations, broker dealers, and mortgage bankers; provided tax planning and tax preparation services for business, trusts, and individuals, designed and installed business accounting systems, and sub-contracted those services with the Small Business Administration and Arizona Research Bureau. Ms. Sylvanus taught accounting at Phoenix College from 1974 through 1985. She graduated from Cleveland State University in 1970 with a B.A. in Accounting and a minor in Economics. She has served on the Board of The American Society of Women Accountants for eight years in every Board position except Secretary.

On April 19, 2016, Dennis Alexander tendered his resignation as Chairman with the Registrant in behalf of the change of control resulting from the Registrants terms of its Purchase Agreement with Canteck Pharma, Inc. Effective April 19, 2016, Mr. Dennis Alexander shall serve as Chief Executive Officer and Director, and Ms. Joanne Sylvanus as Chief Financial Officer, Secretary and Director. Mr. Alexander and Mrs. Sylvanus will each retain 166,500 shares of the Series B Voting Preferred Shares and 172,039,303 shares of the Company’s Common Restricted Stock which was in exchange for each of their return of Series B Voting Preferred Stock in the amount of 333,500. Mr. Alexander will receive a salary of Five Thousand Dollars ($5,000) per month and Ms. Slyvanus, Three Thousand Dollars ($3,000) per month.

Management and operational activities related to development of the Capital Purchase Division have been suspended at the present time due to the inability to raise the capital funding needed for both proof of test and building current or ongoing operations. This potential divisional operation will be reviewed for its potential in the future.

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS

~~The~~On ~~information~~May ~~set~~27, ~~forth~~2016, ~~and~~Reve ~~incorporated~~Technologies, byInc. ~~reference~~(the in“Registrant” ~~3.02~~of “Corporation”) an entity originally organized under the Laws of the State of Nevada on May 11, ~~5.01~~2010 received notice from the Wyoming Secretary of State that it had filed Foreign Profit Corporation Articles of Continuance effective May 27, 2016 whereby the Registrant changed its corporate domicile from the State of Nevada to the State of Wyoming and ~~5.02~~further, along with a summary of ~~this~~the ~~Current~~following ~~Report~~actions ontaken ~~Form~~by ~~8-K~~the isBoard ~~incorporated~~of Directors and by ~~reference~~majority ~~into~~vote ~~this~~of ~~Item~~the ~~5.03.~~Preferred Series B shareholders of the Registrant and effective with the date of even on May 27, 2016:

~~On November 29~~RESOLVED, ~~2015,~~ the ~~Board~~name of ~~Directors of Reve Technologies, Inc. (~~the ~~“Company”)~~corporation ~~approved~~shall bybe ~~its~~immediately ~~consent~~changed tofrom ~~amend~~REVE ~~the~~TECHNOLOGIES, ~~Company’s~~INC. ~~Articles of Incorporation~~ to ~~increase~~CANTECH ~~the~~HOLDING, ~~authorized capital stock~~INC.

AsRESOLVED, athat ~~result~~the ofaddress ~~this~~for ~~filing,~~ the ~~Company’s~~Corporation ~~Articles~~be ofchanged ~~Incorporation~~on ~~were~~the ~~amended~~date toeffective ~~increase~~for the ~~total~~formal ~~authorized~~change ~~capital~~of ~~stock~~domicile ~~from 1,000,000,000 shares~~ to 5Wyoming,~~000,000,000~~ ~~shares~~noted ~~consisting~~by ofthe ~~(i)~~stamped ~~4,990,000,000~~filing ~~shares of voting common stock~~date, ~~$0.001~~to ~~par~~the ~~value~~following ~~per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per shares, which remains unchanged.~~address:

~~For~~CANTECH ~~more information please see Item 5.03 and Exhibit 3.1 in our Current Report on Form 8-K filed on January 14~~HOLDING, ~~2016~~INC.

109 E. 17th Street, Suite 80

Cheyenne, Wyoming 82001

RESOLVED, that Registered Agents of Wyoming is herewith authorized and appointed registered agent for the Corporation with the following address noted:

REGISTERED AGENTS OF WYOMING, LLC

400 E. 20th Street

Chyenne, Wyoming 82001

RESOLVED, it is approved and reconfirmed for the record that On July 20, 2015, the Board of Directors of the Corporation approved and authorized the creation of 1,000,000 shares of Series B Voting Preferred Stock. The Certificate of Designation was filed and effective in the State of Nevada on August 4, 2015 and shall be deemed effectively transferred via the continuance and change of domicile to Wyoming at the effective date of the stamped filing in Wyoming. Each share of Series B Voting Preferred Stock is equal to and counted as 1,000 times the vote of all of the shares of the Corporation (i) common stock, and (ii) other voting preferred stock issued and outstanding on the date of each and every vote or consent of the shareholders of the Company regarding each and every matter submitted to the shareholders of the Company for approval.

RESOLVED, that it is approved upon filing of the Corporations change of domicile to Wyoming to amend Company’s Articles of Incorporation to increase the total authorized capital stock from i) 4,990,000,000 shares of voting common stock to Unlimited shares of voting common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share remain unchanged. In keeping, the shares of Preferred Stock may be issued from time to time in one or more series, in any manner permitted by law, as determined from time to time by the Board of Directors, and stated in the resolution or resolutions providing for the issuance of such shares adopted by the Board of Directors pursuant to authority hereby vested in it. Without limiting the generality of the foregoing, shares in such series shall have such voting powers, full or limited, or no voting powers, and shall have such designations, preferences, and other rights and qualifications, limitations, or restrictions thereof, permitted by law, as shall be stated in the resolution or resolutions providing for the issuance of such shares adopted by the Board of Directors pursuant to authority hereby vested in it. The number of shares of any such series so set forth in such resolution or resolutions may be increased (but not above the total number of authorized shares of Preferred Stock) or decreased (but not below the number of shares thereof then outstanding) by further resolution or resolutions adopted by the Board of Directors pursuant to authority hereby vested in it.

RESOLVED, that the Corporation, organized and existing under the laws of Nevada and having its principal place of business at 300 S. El Camino Real San Clemente, CA 92672 herewith authorizes and approves that this resolution and others needed from time to time to confirm same were adopted by the Corporation Board of Directors at a meeting held on May 13, 2016 and on May 19, 2016 and to which a voting quorum was present maintained throughout and that the resolution adopted at said meeting(s) effectively voted, recorded, and now is in full effect according to the charter, provisions and operating agreement of the Corporation such that it is resolved and effective herewith that the Corporation approves the move of the corporate domicile from the State of Nevada to the State of Wyoming and that continuance upon being effective in Wyoming on the stamped filing date will be dissolved in the former Nevada domicile. The effective date for the change of domicile to Wyoming shall be the stamped filing date in the State of Wyoming.

RESOLVED, that Dennis Alexander, CEO is herewith fully authorized herewith to amend the Articles of Incorporation of the Corporation to effectuate said name change and change of corporate domicile from the State of Nevada to the State of Wyoming and to delegate and or effectuate all persons, entities and items as needed to perform and complete these tasks including any necessary amendments.

ITEM 8.01 OTHER INFORMATION

~~Effective April 19, 2016 the Registrant and certain preferred shareholders of the Registrant entered into a Purchase and Sale Agreement~~ (~~the~~See ~~“Purchase~~Item ~~Agreement”) with Canteck Pharma, Inc~~5.,03 aabove ~~Delaware~~listed ~~corporation~~in ~~(“Canteck”~~this ~~or“CKPH”) and certain majority shareholders of CKPH~~report. ~~Canteck has developed and has patented technology (US 7,479,538 B2~~) and also known as Irreversible Pepsin Fraction (“IPF”). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.

~~The~~A ~~Purchase~~new ~~Agreement~~website ~~sets~~is ~~forth~~currently ~~the~~under ~~plan~~construction ~~through~~for ~~which~~Cantech ~~the Registrant purchases from Seller~~Holding, onInc. ~~the~~The ~~terms~~new ~~and~~website ~~conditions~~address ~~set~~when ~~forth~~completed inwill ~~the~~be ~~Purchase~~located ~~Agreement,~~at Sellers One Hundred Percent (100%) ownership Interest in Canteck Pharma for its current and planned operations for the country of Mexico (“CPMO”) and the exclusive Sub Licensing Agreement therewith for Irreversible Pepsin Fraction specific to the Cancer indication only, for the entire country of Mexico (the “License”);www.cantechholding.com.

About IPF for Cancer treatment

Immunotherapy has the potential to provide an alternative and/or complementary treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.

Unfortunately the immune system by itself can´t recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.

IPF proteins attach to tumor antigens, creating superantigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.

It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.

This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent – fraction and/or its proteins that can attach, serve as the immunogen are already known.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Description
10.1	Purchase and Sale Agreement with Canteck Pharma, Inc.

(d) Exhibits

Exhibit No.	Description
3.1	Articles of Continuance and Certificate of Name Change

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Reve~~Cantech ~~Technologies~~Holding, Inc.

Date: ~~April~~June 253, 2016

By: /s/Dennis Alexander

Dennis Alexander

CEO

Filing Compare · BASELINE PRODUCTIONS, INC.